Watson Gets FTC Nod For $5.5B Actavis Buy, With Concessions
The Federal Trade Commission on Monday cleared Watson Pharmaceuticals Inc.'s proposed €4.25 billion ($5.5 billion) purchase of Actavis Inc. after the generics maker agreed to divest 18 of its drugs to...To view the full article, register now.
Already a subscriber? Click here to view full article